BeOne Medicines (ONC) Long-Term Debt Issuances (2015 - 2025)

BeOne Medicines (ONC) has reported Long-Term Debt Issuances for 10 consecutive years, with $26.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Long-Term Debt Issuances rose 187.2% year-over-year to $26.0 million; the TTM figure through Dec 2025 stood at $911.0 million (up 9962.96% YoY), while the FY2025 annual figure was $911.0 million, up 9962.96% from the prior year.
• Long-Term Debt Issuances declined to $26.0 million in Q4 2025 per ONC's latest filing, from $885.0 million in the prior quarter.
• Across five years, Long-Term Debt Issuances topped out at $885.0 million in Q3 2025 and bottomed at -$22.5 million in Q4 2023.
• Historically, Long-Term Debt Issuances has averaged $81.2 million across 5 years, with a median of $9.1 million in 2024.
• Annual changes were most pronounced in 2024 — Long-Term Debt Issuances sank 234.5% — and 2025, when it jumped 9875.76%.
• BeOne Medicines' Long-Term Debt Issuances stood at $6.0 million in 2021, then surged by 520.9% to $37.4 million in 2022, then slumped by 160.21% to -$22.5 million in 2023, then surged by 140.23% to $9.1 million in 2024, then soared by 187.2% to $26.0 million in 2025.
• Business Quant data shows ONC's Long-Term Debt Issuances at $26.0 million in Q4 2025, $885.0 million in Q3 2025, and $9.1 million in Q4 2024.